CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue
Housing	$ 0	$ 0	$ 80,650	$ 0
Commercial rental - related party	0	0	0	0
Tissue array products	111,929	132,941	265,584	422,820
Total revenue	111,929	132,941	346,234	422,820
Cost of Sales
Housing	0	0	47,145	0
Commercial rental - related party	4,500	182	38,164	21,444
Tissue array products	87,141	96,747	227,368	280,082
Total cost of sales	91,641	96,929	312,677	301,526
Gross Profit	20,288	36,012	33,557	121,294
Operating Expenses:
Salaries and wages	56,446	82,085	162,206	178,048
Depreciation and amortization	2,456	23,992	16,308	63,428
Bad debt expense	0	0	0	6,690
Professional fees	9,061	11,547	66,810	66,111
Selling and distribution expenses	1,411	1,622	6,005	7,726
Other general and administrative expenses	45,607	7,572	218,844	142,589
Total Operating Expenses	114,981	126,818	470,173	464,592
Loss from Operations	(94,693)	(90,806)	(436,616)	(343,298)
Other Income (Expense)
Interest expenses	(57,894)	(66,564)	(143,380)	(174,362)
Other income (expense), net	56	(2,931)	(22,739)	21,635
Total Other Expense, Net	(57,838)	(69,495)	(166,119)	(152,727)
Loss before Income Taxes	(152,531)	(160,301)	(602,735)	(496,025)
Income Tax Expense	74	104	(1,664)	388
Net loss	(152,605)	(160,405)	(601,071)	(496,413)
Less: Net loss attributable to the	(74,379)	(37,555)	(74,379)	(101,490)
Net loss attributable to CYBRDI, INC.	(78,226)	(122,850)	(526,692)	(394,923)
Foreign currency translation loss	(18,468)	182,387	(134,295)	178,978
Comprehensive loss	$ (96,694)	$ 59,537	$ (660,987)	$ (215,945)
Net Loss Per Common Share
Basic and Diluted	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Weighted Average Number of Shares Outstanding
Basic and Diluted	120,225,323	120,225,323	120,225,323	120,225,323